BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18042233)

  • 1. Epstein-Barr virus reactivation and multiple sclerosis.
    Torkildsen Ø; Nyland H; Myrmel H; Myhr KM
    Eur J Neurol; 2008 Jan; 15(1):106-8. PubMed ID: 18042233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
    Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
    Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus and disease activity in multiple sclerosis.
    Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis and Epstein-Barr virus.
    Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
    JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients.
    Deeba E; Koptides D; Gaglia E; Constantinou A; Lambrianides A; Pantzaris M; Krashias G; Christodoulou C
    Mol Immunol; 2019 Jan; 105():270-275. PubMed ID: 30562647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
    Castellazzi M; Delbue S; Elia F; Gastaldi M; Franciotta D; Rizzo R; Bellini T; Bergamaschi R; Granieri E; Fainardi E
    Dis Markers; 2015; 2015():901312. PubMed ID: 26101453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
    Kvistad S; Myhr KM; Holmøy T; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Løken-Amsrud KI; Lilleås F; Midgard R; Njølstad G; Pedersen T; Benth JŠ; Wergeland S; Torkildsen O
    Mult Scler; 2014 Dec; 20(14):1833-40. PubMed ID: 24842958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
    Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
    JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of immunoblot-based assay for detecting Epstein-Barr virus viral capsid antibodies].
    Altuğlu I; Aksoy A; Zeytinoğlu A; Orman M
    Mikrobiyol Bul; 2010 Apr; 44(2):231-6. PubMed ID: 20549957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
    Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
    Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
    Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
    Neurology; 2004 Jun; 62(12):2277-82. PubMed ID: 15210894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies.
    Chen CJ; Lin KH; Lin SC; Tsai WC; Yen JH; Chang SJ; Lu SN; Liu HW
    J Rheumatol; 2005 Jan; 32(1):44-7. PubMed ID: 15630723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis.
    Touge C; Agawa H; Sairenji T; Inoue Y
    Arch Virol; 2006 May; 151(5):895-903. PubMed ID: 16362642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
    Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
    JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus persistence and reactivation in neuromyelitis optica.
    Masuda S; Mori M; Arai K; Uzawa A; Muto M; Uchida T; Masuda H; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1137-42. PubMed ID: 25433035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection.
    Obel N; Høier-Madsen M; Kangro H
    APMIS; 1996 Jun; 104(6):424-8. PubMed ID: 8774671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome.
    Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
    In Vivo; 2004; 18(2):101-6. PubMed ID: 15113035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis.
    Wagner HJ; Munger KL; Ascherio A
    Eur J Neurol; 2004 Dec; 11(12):833-4. PubMed ID: 15667414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.
    Lindsey JW; Hatfield LM; Vu T
    Eur J Neurol; 2010 Oct; 17(10):1263-9. PubMed ID: 20402753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.
    Aalto SM; Linnavuori K; Peltola H; Vuori E; Weissbrich B; Schubert J; Hedman L; Hedman K
    J Med Virol; 1998 Nov; 56(3):186-91. PubMed ID: 9783683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.